Cytoreductive nephrectomy in metastatic renal cancer - less is more.
作者信息
Bex Axel, Haanen John
机构信息
Department of Urology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Department of Immunology and Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
出版信息
Nat Rev Clin Oncol. 2018 Oct;15(10):595-596. doi: 10.1038/s41571-018-0065-4.
PMID:29967447
Abstract
摘要
相似文献
1
Cytoreductive nephrectomy in metastatic renal cancer - less is more.转移性肾癌的减瘤性肾切除术——少即是多。
Nat Rev Clin Oncol. 2018 Oct;15(10):595-596. doi: 10.1038/s41571-018-0065-4.
2
Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.舒尼替尼与减瘤性肾切除术治疗转移性肾细胞癌
J Urol. 2019 Mar;201(3):453-454. doi: 10.1016/j.juro.2018.09.050.
3
Has the Age of Cytoreductive Nephrectomy Come to an End?: Commentary on: Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma.减瘤性肾切除术的时代已经结束了吗？：对《舒尼替尼单药治疗或肾切除术后治疗转移性肾细胞癌》的评论
Urology. 2018 Nov;121:1-2. doi: 10.1016/j.urology.2018.07.007. Epub 2018 Aug 2.
4
Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to Be.转移性肾细胞癌中的减瘤性肾切除术：并非如其所宣称的那样。
JAMA Oncol. 2019 Feb 1;5(2):171-172. doi: 10.1001/jamaoncol.2018.5503.
5
Cytoreductive nephrectomy is dead, long live cytoreductive nephrectomy.减瘤性肾切除术已死，减瘤性肾切除术万岁。
BJU Int. 2019 Jul;124(1):6-7. doi: 10.1111/bju.14675. Epub 2019 Feb 3.
6
Editorial Comment: Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.编者按：接受舒尼替尼治疗的同步转移性肾细胞癌患者中即刻与延迟减瘤性肾切除术的比较：SURTIME随机临床试验
Int Braz J Urol. 2020 May-Jun;46(3):476. doi: 10.1590/S1677-5538.IBJU.2020.03.12.
7
Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?回复：阿诺·梅让、阿兰·拉沃德、西蒙·泰泽纳斯等。舒尼替尼单药治疗或肾切除术后治疗转移性肾细胞癌。《新英格兰医学杂志》2018年；379:417 - 27：CARMENA试验：这是否意味着透明细胞肾细胞癌患者减瘤性肾切除术的终结？
Eur Urol Oncol. 2019 May;2(3):340-341. doi: 10.1016/j.euo.2018.08.002. Epub 2018 Aug 24.
8
Cytoreductive nephrectomy: questions remain after CARMENA.减瘤性肾切除术：CARMENA研究后仍存在疑问。
Nat Rev Urol. 2018 Sep;15(9):530-532. doi: 10.1038/s41585-018-0064-3.
9
Surgical Safety of Cytoreductive Nephrectomy Following Systemic Therapy: What Should We Look For?全身治疗后减瘤性肾切除术的手术安全性：我们应该关注什么？
Eur Urol. 2019 Oct;76(4):441-442. doi: 10.1016/j.eururo.2019.07.007. Epub 2019 Jul 18.
10
The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.细胞减灭性肾切除术在转移性肾细胞癌中的不断演变的角色。
Curr Opin Urol. 2019 Sep;29(5):507-512. doi: 10.1097/MOU.0000000000000657.
引用本文的文献
1
Surgical intervention in renal cell carcinoma patients with lung and bronchus metastasis is associated with longer survival time: a population-based analysis.对伴有肺和支气管转移的肾细胞癌患者进行手术干预与更长的生存时间相关：一项基于人群的分析。
Ann Transl Med. 2019 Jul;7(14):323. doi: 10.21037/atm.2019.06.02.
Zotero 插件